Entropy Technologies LP Acquires Shares of 8,674 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Entropy Technologies LP bought a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 8,674 shares of the company’s stock, valued at approximately $275,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its stake in IDEAYA Biosciences by 38.4% in the second quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock worth $117,000 after buying an additional 927 shares in the last quarter. Swiss National Bank raised its position in shares of IDEAYA Biosciences by 30.9% in the 1st quarter. Swiss National Bank now owns 111,400 shares of the company’s stock worth $4,888,000 after acquiring an additional 26,300 shares in the last quarter. Quest Partners LLC bought a new position in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $41,000. Price T Rowe Associates Inc. MD lifted its stake in shares of IDEAYA Biosciences by 13.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,052,500 shares of the company’s stock valued at $177,825,000 after purchasing an additional 486,222 shares during the period. Finally, Scientech Research LLC boosted its position in shares of IDEAYA Biosciences by 362.3% during the second quarter. Scientech Research LLC now owns 27,708 shares of the company’s stock valued at $973,000 after purchasing an additional 21,714 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ:IDYA opened at $26.64 on Friday. The business has a 50-day simple moving average of $31.42 and a two-hundred day simple moving average of $36.36. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -11.43 and a beta of 0.86. IDEAYA Biosciences, Inc. has a fifty-two week low of $26.41 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter in the prior year, the company posted ($0.46) EPS. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

IDYA has been the subject of a number of research reports. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Stifel Nicolaus lifted their price target on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Citigroup dropped their price objective on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Cantor Fitzgerald assumed coverage on shares of IDEAYA Biosciences in a report on Tuesday, October 15th. They set an “overweight” rating for the company. Finally, Leerink Partnrs downgraded IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.91.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.